CD4 and graft versus host disease: These findings concur with evidence which demonstrates the protective capacity of immunosuppressive Bregs in the prevention of allograft rejection in renal, liver and lung transplantation recipients and in the development of graft-versus-host disease in stem cell recipients, and with increased frequencies of CD4+ve T cells in the colons of FMT-treated mice, respectively [72,73].